NIP3-2 Antibody

What is BNIP3 and what structural domains characterize this protein?

BNIP3 is a 194 amino acid, 21.5 kDa proapoptotic protein belonging to the Bcl-2 protein family. The protein contains a single Bcl-2 homology 3 (BH3) domain, which is crucial for its proapoptotic function, and a C-terminal transmembrane domain that is required for mitochondrial localization, homodimerization, and regulation of its proapoptotic function. BNIP3 was originally identified as one of several proteins that interact with discrete domains of Bcl-2 and the adenovirus E1B 19 kDa protein, which protects against virally-induced cell death . The dimeric mitochondrial protein is known to induce apoptosis even in the presence of BCL2, indicating its potent cell death-inducing properties .

How does BNIP3 differ from its homolog BNIP3L/NIX?

BNIP3 shares 56% identity with its related protein NIX (also known as BNIP3L). Both proteins contain similar structural domains including PEST, BH3, and transmembrane domains. Like BNIP3, NIX is also induced by hypoxia, localizes to mitochondria, and can induce cell death. Furthermore, NIX is upregulated in heart muscle following ischemic injury and in human breast tumors, similar to patterns observed with BNIP3. These similarities suggest functional overlap between these BH3-only Bcl-2 family members, though their specific regulatory mechanisms may differ in various cellular contexts .

What are the typical applications for BNIP3 antibodies in basic research?

BNIP3 antibodies are essential research tools employed in multiple experimental applications, including:

• Western blot detection of BNIP3 expression in various cell lines (e.g., A549 human lung carcinoma and MCF-7 human breast cancer cells)

• Immunoprecipitation assays to isolate and study native BNIP3 protein

• Detection of post-translational modifications, particularly phosphorylation and O-β-glycosylation

• Analysis of protein-protein interactions, such as BNIP3 binding to BCL2 or LC3

• Evaluation of BNIP3 expression in response to cellular stressors such as hypoxia

What is the optimal protocol for detecting BNIP3 by Western blot?

For Western blot detection of BNIP3, researchers should follow these methodological guidelines:

• Sample preparation: Prepare cell lysates from appropriate cell lines (e.g., A549 or MCF-7), potentially including both untreated and treated samples (e.g., with 150 μM CoCl₂ for 16 hours to mimic hypoxia)

• Protein separation: Resolve proteins on a 12% SDS-PAGE gel under reducing conditions

• Transfer: Transfer proteins to PVDF membrane using standard wet or semi-dry transfer methods

• Blocking: Block non-specific binding sites with 3-5% non-fat milk or BSA

• Primary antibody: Probe with anti-BNIP3 antibody (e.g., 1 μg/mL of Human BNIP3 Antigen Affinity-purified Polyclonal Antibody)

• Secondary antibody: Apply appropriate HRP-conjugated secondary antibody (e.g., Anti-Goat IgG)

• Development: Visualize using ECL (enhanced chemiluminescence) detection

• Analysis: BNIP3 typically appears as a band at approximately 30 kDa, though the predicted size is 21.5 kDa, likely due to post-translational modifications

How can researchers effectively immunoprecipitate BNIP3 for downstream analyses?

For immunoprecipitation of native BNIP3, the following protocol has been validated:

• Antibody binding: Incubate 100 μg of anti-BNIP3 antibodies with immobilized protein A columns for 15 minutes

• Washing: Wash columns 5 times with binding/wash buffer

• Cross-linking: Cross-link bound antibodies to protein A using DSS (disuccinimidyl suberate)

• Sample addition: Add 100 μg of soluble antigen (e.g., cell or tissue lysate) and incubate for 1 hour at room temperature

• Washing: Remove unbound antigens by washing 5 times with wash buffer

• Elution: Elute bound antigens with appropriate elution buffer

• Analysis: The immunoprecipitated BNIP3 can then be analyzed for post-translational modifications or protein interactions using western blotting

For co-immunoprecipitation studies examining BNIP3 interactions with other proteins (e.g., LC3 or JNK), researchers should co-transfect cells with tagged versions of both proteins (e.g., Flag-BNIP3 and GFP-LC3 or HA-JNK) before performing immunoprecipitation with antibodies against the appropriate tag .

How does phosphorylation regulate BNIP3 function, and what methods reveal these modifications?

BNIP3 phosphorylation, particularly at Ser60, plays a critical role in regulating its function in mitophagy. Research has demonstrated that:

• Phosphorylation status changes during hypoxia: BNIP3 phosphorylation increases in the early stage of hypoxia and decreases in later stages

• Ser60 is the primary phosphorylation site: Mutation of Ser60 to alanine (S60A) significantly reduces BNIP3 phosphorylation

• Phosphorylation affects LC3 binding: Phosphorylation at Ser60 enhances the binding affinity between BNIP3 and LC3-II, promoting mitophagy

• Phosphomimetic mutations enhance activity: BNIP3-S60D or S60E mutations that mimic phosphorylation enhance mitophagy, while phospho-deficient mutations (S60A) inhibit mitophagy

To detect BNIP3 phosphorylation, researchers can use:

• Phospho-specific antibodies directed against phospho-Ser60

• Immunoprecipitation followed by western blotting with antibodies against phospho-MAPK/CDK substrates

• Mobility shift assays on SDS-PAGE, as phosphorylated BNIP3 typically migrates more slowly

What kinases phosphorylate BNIP3 and how can researchers identify specific kinase-substrate relationships?

JNK1 and JNK2 have been identified as the primary kinases responsible for BNIP3 phosphorylation, particularly at Ser60. To establish this kinase-substrate relationship, researchers employed the following methods:

• Kinase inhibitor screening: Treatment with specific MAP kinase inhibitors (particularly JNK inhibitors) reduced BNIP3 phosphorylation

• siRNA knockdown: Selective knockdown of Jnk1 and Jnk2, but not Jnk3, Erk1, Erk2, or Erk5, resulted in decreased BNIP3 phosphorylation

• Co-immunoprecipitation: JNK1 and JNK2 were shown to physically interact with BNIP3 in cells co-transfected with Flag-BNIP3 and HA-JNK1 or HA-JNK2

• Direct kinase assays: In vitro kinase assays can further confirm the direct phosphorylation of BNIP3 by purified JNK proteins

These methodologies provide a framework for researchers investigating kinase-substrate relationships for other post-translational modifications of BNIP3 or related proteins .

How does BNIP3 contribute to mitophagy regulation, and what experimental approaches best assess this function?

BNIP3 plays a critical role in regulating mitophagy, particularly under hypoxic conditions. This function appears to be regulated by both protein expression levels and post-translational modifications. The following experimental approaches are effective for studying BNIP3-mediated mitophagy:

• LC3-II quantification: Western blot analysis of LC3-II levels (autophagosome marker) in control versus BNIP3-manipulated cells

• Mitochondrial marker assessment: Monitoring levels of mitochondrial proteins (e.g., TOMM20) to track mitochondrial degradation

• siRNA knockdown: Using Bnip3 siRNA to assess the specific contribution of BNIP3 to mitophagy in different conditions

• Phosphorylation site mutants: Expressing BNIP3 phospho-mutants (S60A) or phospho-mimetics (S60D/E) to evaluate the impact of phosphorylation on mitophagy

• Fluorescence microscopy: Visualizing mitophagy by observing co-localization of LC3 puncta with mitochondria and quantifying mitochondrial mass

Research has shown that while hypoxia increases BNIP3 expression, the relationship between protein levels and mitophagy activity is not straightforward. For instance, in 10% O₂ conditions, knockdown of Bnip3 attenuated mitophagy, but similar knockdown in 0.3% O₂ had less impact, suggesting that regulation involves factors beyond mere protein levels .

What is the apparent paradox in BNIP3 function, and how do researchers reconcile contradictory findings?

BNIP3 exhibits seemingly contradictory functions in cell fate determination. While it was initially characterized as a pro-apoptotic protein that induces cell death, subsequent research has revealed greater complexity:

To reconcile these contradictory findings, researchers should consider:

• Cellular context: Different cell types may have different downstream effectors of BNIP3 signaling

• Microenvironmental conditions: Oxygen levels, nutrient availability, and other stressors influence BNIP3 function

• Post-translational modifications: Phosphorylation status affects BNIP3 activity and binding partners

• Temporal dynamics: Early vs. late responses to BNIP3 induction may differ

• Expression levels: Low vs. high expression may trigger different pathways

• Interaction partners: Availability of binding partners may direct BNIP3 toward specific functions

Researchers investigating these paradoxical functions should employ multiple cell death assays, carefully control experimental conditions, and examine context-dependent factors to determine the specific role of BNIP3 in their system of interest .

How does hypoxia regulate BNIP3 expression and function, and what are the methodological considerations for hypoxia experiments?

Hypoxia is a key regulator of BNIP3 expression and function through the following mechanisms:

• Transcriptional induction: Under conditions of prolonged oxygen deprivation, hypoxia-induced factor HIF1-alpha activates BNIP3 expression

• Post-translational regulation: Hypoxia influences BNIP3 phosphorylation status, with increased phosphorylation in early hypoxia and decreased phosphorylation in late hypoxia

• Functional modulation: Hypoxia affects BNIP3's interactions with partners such as LC3, influencing its role in mitophagy

For hypoxia experiments with BNIP3, researchers should consider these methodological approaches:

• Chemical hypoxia mimetics: CoCl₂ (150 μM for 16 hours) can be used to induce BNIP3 expression as demonstrated in A549 and MCF-7 cells

• Controlled oxygen chambers: Different oxygen concentrations (e.g., 10% O₂ vs. 0.3% O₂) produce distinct effects on BNIP3 function

• Time-course studies: BNIP3 responses change over time during hypoxia exposure

• Protein fractionation: Analyzing both total BNIP3 levels and subcellular distribution (e.g., mitochondrial localization)

• Functional readouts: Assessing both BNIP3 expression and downstream functions (e.g., mitophagy, cell death)

These considerations help researchers design appropriate hypoxia experiments to study BNIP3 regulation and function in a physiologically relevant context .

What are common challenges in detecting BNIP3 by western blot, and how can researchers overcome them?

Researchers may encounter several challenges when detecting BNIP3 by western blot:

• Size discrepancy: While the predicted size of BNIP3 is 21.5 kDa, it often appears at approximately 30 kDa on western blots due to post-translational modifications

• Multiple bands: BNIP3 can appear as multiple bands representing monomers, dimers, and modified forms

• Low expression levels: Basal BNIP3 expression can be low in some cell types, making detection difficult

• Antibody specificity: Some antibodies may cross-react with the related protein BNIP3L/NIX

To overcome these challenges, researchers should:

• Use positive controls (e.g., 293T cells transfected with BNIP3 or hypoxia-treated A549/MCF-7 cells)

• Optimize protein loading (typically 20-50 μg of total protein)

• Consider using reducing conditions to focus on monomeric forms

• Test multiple antibodies to find optimal specificity and sensitivity

• Induce BNIP3 expression with hypoxia or hypoxia mimetics before analysis

• Include appropriate size markers to accurately identify BNIP3 bands

• Consider using phosphatase treatment to collapse multiple phosphorylated forms into a single band if phosphorylation is not the focus of study

How can researchers verify BNIP3 antibody specificity and optimize immunoprecipitation protocols?

To ensure antibody specificity and optimize immunoprecipitation of BNIP3, researchers should:

• Verify antibody specificity:

  • Test antibody recognition of recombinant BNIP3 versus BNIP3L/NIX

  • Include siRNA knockdown controls to confirm band specificity

  • Use BNIP3 overexpression as a positive control

  • Test antibody in BNIP3 knockout/null cell lines if available

• Optimize immunoprecipitation:

  • Cross-link antibodies to protein A/G beads to prevent antibody contamination in eluates

  • Use gentle lysis buffers to preserve protein interactions (e.g., 1% NP-40 or 0.5% Triton X-100)

  • Include protease and phosphatase inhibitors to prevent protein degradation and modification changes

  • Optimize antibody:antigen ratios (typically 100 μg antibody to 100-500 μg protein lysate)

  • Consider pre-clearing lysates with protein A/G beads alone to reduce non-specific binding

  • Use specific elution conditions that minimize co-elution of non-specific proteins

• Validate successful immunoprecipitation:

  • Confirm BNIP3 presence in immunoprecipitates by western blot

  • Include isotype control antibodies as negative controls

  • Verify enrichment by comparing input, unbound, and eluted fractions